Amber Nigam’s article discusses current and future trends in the pharmaceutical industry, focusing on innovation, cost, and access. A key example is GLP-1 drugs, which help with weight management and diabetes (Nigam, 2024). These drugs are expensive, leading to different responses from insurance companies. Some include them in their coverage, while others do not; this reflects the industry’s struggle to balance new treatments with their costs (Nigam, 2024).
Nigam also points out that partnerships between drug companies and online pharmacies, like Amazon Pharmacy, are becoming more common. These collaborations aim to make new drugs more accessible and affordable. The article highlights a shift towards personalized care plans, where treatments are tailored to individual needs, supported by AI technology.
Looking ahead, Nigam predicts that new patents and drug regulations will continue to change how drugs are accessed and priced. Overall, the future of the pharmaceutical industry will involve balancing new medical advances with cost and access challenges, with ongoing discussions shaping how new treatments are developed and priced (Nigam, 2024).
Nigam’s article is relevant to the theme of adapting to challenges and finding solutions. Just as artists with chronic conditions adapt their work, the pharmaceutical industry is adapting to new drugs and costs to improve patient care. The focus on personalized treatments and collaboration mirrors the theme of resilience in overcoming obstacles.
Nigam, A. (2024, August 13). Council Post: State of The Pharma Industry: Present and Future. Forbes. https://www.forbes.com/councils/forbesbusinesscouncil/2024/04/08/state-of-the-pharma-industry-present-and-future/
OpenAI. (2024). ChatGPT (Sept 16 version) [Large language model]. https://chat.openai.com/chat
